Antimicrobial susceptibility profiles of oropharyngeal viridans group streptococci isolates from cystic fibrosis and non-cystic fibrosis patients

被引:2
|
作者
Alvarez, M
Alvarez, ME
Maiz, L
Asensio, A
Baquero, F
Canton, R [1 ]
机构
[1] Hosp Ramon y Cajal, Microbiol Serv, E-28034 Madrid, Spain
[2] Hosp Ramon y Cajal, Unidad Fibrosis Quist, E-28034 Madrid, Spain
[3] Hosp Ramon y Cajal, Serv Med Prevent, E-28034 Madrid, Spain
来源
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE | 1998年 / 4卷 / 02期
关键词
D O I
10.1089/mdr.1998.4.123
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The antimicrobial susceptibility profile of 77 oropharyngeal viridans streptococci isolates from 34 cystic fibrosis (CF) patients and 58 isolates from 43 healthy non-CF patients were studied by the E-test and the standard disk diffusion methods. Overall penicillin and cefotaxime resistances (intermediate plus resistant isolates) were significantly higher (p < 0.05) among CF isolates (72.7% and 45.5%, respectively) than among non-CF isolates (51.7% and 15.5%, respectively), No significant difference was observed in overall (intermediate plus resistant) erythromycin resistance rates, although high-level erythromycin resistance (greater than or equal to 32 mu g/mL) was more frequently found in CP isolates (24.6%) than in non-CF isolates (12.1%), An unexpected high percentage of isolates showed low level erythromycin resistance (MIC range, 0.5-15 mu g/mL): 41.5% in cystic fibrosis and 46.5% in non-CF isolates. No significant differences were observed regarding the percentage of colonized patients with at least one penicillin-resistant isolate. On the contrary, colonization with cefotaxime (p < 0.001) or erythromycin (p = 0.014) resistant isolates were significantly more prevalent in CF patients. Similar tetracycline and chloramphenicol resistance rates were observed for both groups. Viridans isolates resistant to a single antibiotic were more prevalent among non-CF patients and multiple resistance was higher among CF patients. Prior antibiotic exposure could result in differences in beta-lactam resistance and colonization rates with resistant isolates between both groups. None of the non-CF patients was previously treated with antimicrobials for a period of three months before sampling. In contrast, 94.1% of CF patients were treated with antimicrobials within the same period; 65.6% with beta-lactam antibiotics. Patients with CF disease, frequently exposed to antimicrobials, may be a reservoir of viridans streptococci isolates with resistance determinants, particularly to beta-lactam antibiotics.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 50 条
  • [1] Antimicrobial susceptibility testing of cystic fibrosis and non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods
    Bradbury, R. S.
    Tristram, S. G.
    Roddam, L. F.
    Reid, D. W.
    Inglis, T. J. J.
    Champion, A. C.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2011, 68 (01) : 1 - 4
  • [2] Molecular Characterization of Achromobacter Isolates from Cystic Fibrosis and Non-Cystic Fibrosis Patients in Madrid, Spain
    Barrado, Laura
    Branas, Patricia
    Angeles Orellana, M.
    Teresa Martinez, M.
    Garica, Gloria
    Otero, Joaquin R.
    Chaves, Fernando
    JOURNAL OF CLINICAL MICROBIOLOGY, 2013, 51 (06) : 1927 - 1930
  • [3] Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients
    AbdulWahab, Atqah
    Taj-Aldeen, Saad J.
    Ibrahim, Emad
    Abdulla, Shaikha H.
    Muhammed, Ramees
    Ahmed, Irshad
    Abdeen, Yasmine
    Sadek, Omnia
    Abu-Madi, Marawan
    INFECTION AND DRUG RESISTANCE, 2014, 7 : 309 - 316
  • [4] Genetic relatedness of Burkholderia contaminans clinical isolates from cystic fibrosis and non-cystic fibrosis patients in Argentina
    Cipolla, Lucia
    Prieto, Monica
    Faccone, Diego
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2022, 16 (05): : 835 - 842
  • [5] EVALUATION OF BIOFILM PRODUCTION BY PSEUDOMONAS AERUGINOSA ISOLATES RECOVERED FROM CYSTIC FIBROSIS AND NON-CYSTIC FIBROSIS PATIENTS
    Perez, L. R. R.
    Costa, M. C. N.
    Freitas, A. L. P.
    Barth, A. L.
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2011, 42 (02) : 476 - 479
  • [6] Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis Preface
    Jones, Andrew M.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (02) : 167 - 167
  • [7] Fungi in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis
    Moss, Richard B.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 36 (02) : 207 - 216
  • [8] Antimicrobial treatment of non-cystic fibrosis bronchiectasis
    Grimwood, Keith
    Bell, Scott C.
    Chang, Anne B.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2014, 12 (10) : 1277 - 1296
  • [9] Species distribution of Burkholderia cepacia complex isolates in cystic fibrosis and non-cystic fibrosis patients in New Zealand
    Pope, Christopher E.
    Short, Patricia
    Carter, Philip E.
    JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (06) : 442 - 446
  • [10] The Presence of Quorum-Sensing Genes in Pseudomonas isolates Infecting Cystic Fibrosis and Non-cystic Fibrosis Patients
    Rodrigues Perez, Leandro Reus
    Mombach Pinheiro Machado, Alice Beatriz
    Barth, Afonso Luis
    CURRENT MICROBIOLOGY, 2013, 66 (04) : 418 - 420